Boehringer Ingelheim inaugurates the largest European development center for biotechnology Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as…
Lilly to Divest BAQSIMI to Amphastar In an effort to continue expanding the availability of BAQSIMI® to patients, Eli Lilly and Company (NYSE: LLY) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) have entered into a definitive agreement for Lilly to divest BAQSIMI worldwide to Amphastar, a global pharmaceutical company…
Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA Daiichi Sankyo (TSE: 4568) today announced thatthe U.S. Food and Drug Administration (FDA) has extended the review period for the New DrugApplication (NDA) of quizartinib in…
WHO releases new guide on developing national programmes for age-friendly cities and communities As population ageing and urbanization rapidly progress worldwide, making our cities and communities more age-friendly is crucial to maximise the opportunities offered by longer lives. A new…
WHO/UNICEF have started the Immunization Annual Data Collection Process We are pleased to announce that the World Health Organization (WHO) / United Nations Children’s Fund (UNICEF) electronic Joint Reporting Form on Immunization (eJRF), is open for completion since March 1st…
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer RAHWAY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results…
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. RAHWAY, N.J. & SAN DIEGO–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (“Prometheus”) (Nasdaq: RXDX) today announced that the companies have…
Merck Named One of Fortune’s 2023 100 Best Companies to Work For® RAHWAY, N.J.‐‐(3BL MEDIA)‐‐Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has earned a place on the Fortune 100 Best Companies to Work For list…
AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR AstraZeneca will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research (AACR) Annual Meeting, 14…
ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies AstraZeneca will highlight new data across its Vaccines and Immune Therapies portfolio at the 33rd European Congress of Clinical Microbiology &…
Lynparza and Imfinzi combination improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Phase III trial Positive high-level results from a planned interim analysis of the DUO-O Phase III trial showed treatment…
ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction…